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Abstract.
Background: Sensitive and specific instruments are required to screen for cognitive impairment (CI) in busy clinical practice.
The Montreal Cognitive Assessment (MoCA) is widely validated but few studies compare it to tests designed specifically to
detect mild cognitive impairment (MCI).
Objective: Comparison of two “MCI specific” screens: the Quick Mild Cognitive Impairment screen (Qmci) and MoCA.
Methods: Patients with subjective memory complaints (SMC; n = 73), MCI (n = 103), or dementia (n = 274), were referred
to a university hospital memory clinic and underwent comprehensive assessment. Caregivers, without cognitive symptoms,
were recruited as normal controls (n = 101).
Results: The Qmci was more accurate than the MoCA in differentiating MCI from controls, area under the curve (AUC)
of 0.90 versus 0.80, p = 0.009. The Qmci had greater (AUC 0.81), albeit non-significant, accuracy than the MoCA (AUC
0.73) in separating MCI from SMC, p = 0.09. At its recommended cut-off (<62/100), the Qmci had a sensitivity of 90% and
specificity of 87% for CI (MCI/dementia). Raising the cut-off to <65 optimized sensitivity (94%), reducing specificity (80%).
At <26/30 the MoCA had better sensitivity (96%) but poor specificity (58%). A MoCA cut-off of <24 provided the optimal
balance. Median Qmci administration time was 4.5 (±1.3) minutes compared with 9.5 (±2.8) for the MoCA.
Conclusions: Although both tests distinguish MCI from dementia, the Qmci is particularly accurate in separating MCI
from normal cognition and has shorter administration times, suggesting it is more useful in busy hospital clinics. This study
reaffirms the high sensitivity of the MoCA but suggests a lower cut-off (<24) in this setting.
Keywords: Cognitive screening, dementia, mild cognitive impairment, Montreal Cognitive Assessment, Quick Mild Cognitive
Impairment screen
INTRODUCTION
As society ages, the prevalence of cognitive impair-
ment (CI) is expected to rise [1, 2], resulting in
increased numbers of older people presenting with
memory complaints. Memory loss is a spectrum
from subjective memory complaints (SMC), which is
∗Correspondence to: Ro´na´n O’Caoimh, Centre for Gerontol-
ogy and Rehabilitation, University College Cork, St Finbarr’s Hos-
pital, Douglas Road, Cork City, Ireland. Tel.: +353 21 4205976;
Fax: +353 21 4922309; E-mail: rocaoimh@hotmail.com.
characterised by normal cognition on neuropsycho-
logical testing, to mild cognitive impairment (MCI)
and dementia. SMC are common, increase with age,
and are associated with cognitive decline [3, 4]. MCI
represents a heterogeneous group of disorders of
memory impairment, characterized by objective and
subjective memory loss but preserved function [5, 6],
with variable progression to dementia [7]. Different
treatment approaches are recommended depending
on where patients fall on the spectrum [8]. Thus, sen-
sitive and specific instruments are required to screen
for CI, particularly in busy clinical settings.
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The Montreal Cognitive Assessment (MoCA) is
a well-established cognitive screen, highly sensitive
at differentiating MCI from normal cognition and
dementia [9] and is widely validated against the most
commonly used instrument, the Mini-Mental State
Examination (MMSE) [10, 11], in multiple settings
[12–14], disorders [15–17] and languages [18–21].
Normative population data are also available [22,
23]. The MoCA overcomes the high ceiling effects
and educational bias associated with the MMSE [24],
has fewer practice effects and is available in multi-
ple formats [24]. Although the MoCA is increasingly
considered the short cognitive instrument of choice,
its use as a screen presents some challenges. It is
long, taking at least 10 minutes to complete [9], and
its subtest scores are criticized for having low accu-
racy when predicting impairment in their respective
cognitive domains [25]. Its specificity at its recom-
mended cut-off (<26) is low, between 35% [12] and
50% [14], lower than that reported in the original
validation cohort [9]. Recently, it has been suggested
that lowering its cut-off will improve its specificity
without adversely affecting its sensitivity [26].
The Quick Mild Cognitive Impairment screen
(Qmci), presented in Supplementary Material 1,
is a short screening test for CI that was devel-
oped as a rapid, valid, and reliable instrument for
the early detection and differential diagnosis of
MCI and dementia [27, 28]. It correlates with the
standardized Alzheimer‘s Disease Assessment Scale-
cognitive section, Clinical Dementia Rating scale and
the Lawton-Brody activities of daily living scale [29].
Neither the MoCA nor the Qmci are usually com-
pared to short screens designed specifically to detect
MCI as well as dementia. Furthermore, little is known
about the optimal cut-off scores for either instrument
in patients referred to a clinic. Given this, we chose to
compare the Qmci and MoCA, two “MCI specific”
screening instruments, in a geriatric memory clinic
population.
METHODS
Participants
Patients referred for investigation of memory loss
were recruited from a university hospital mem-
ory clinic in Cork City, Ireland, between March
2012 and December 2014. Alzheimer’s disease and
vascular type dementia were classified using the
Diagnostic and Statistical Manual of Mental Dis-
orders (4th-edition) [30]. Severity was correlated
with the Reisberg FAST scale [31]. Early demen-
tia was defined clinically as noticeable deficits with
demanding organizational tasks, e.g., decreased job
function (as opposed to ‘prodromal Alzheimer’s
disease’, which is synonymous with ‘MCI due to
Alzheimer’s disease’ and defined by biomarkers).
Mild dementia was defined if assistance in com-
plicated instrumental activities such as handling
medications and finances etc. was required. MCI
was diagnosed using Petersen’s criteria [32] accord-
ing to the National Institute on Aging-Alzheimer’s
Association workgroup diagnostic guidelines [6].
Frontotemporal dementia (FTD) was diagnosed clin-
ically referencing the Lund-Manchester Criteria [33].
FTD MCI was diagnosed clinically with reference to
proposed criteria [34]. Parkinson’s disease demen-
tia (PDD) and MCI were defined by the Movement
Disorder Society Guidelines [35, 36], Lewy body
dementia (LBD) and MCI using the third report
of the LBD Consortium [37]. SMC was defined
as subjective non-progressive memory complaints
in patients without objective cognitive deficits or
functional decline, scoring ‘poor’ or ‘fair’ on a
five-point Likert scale in response to the question
“how is your memory?” [38]. Normal controls were
recruited by convenience sampling from healthy
participants, usually caregivers, without cognitive
problems accompanying the patients.
Those with active depression (n = 23), aged <45
years (n = 22), declining consent (n = 3), with an
unclear diagnosis (n = 21), unable to communicate
in English (n = 2), or with resolving delirium in
patients recently discharged from hospital (n = 2),
were excluded. Depression was excluded clinically
and screened with the Geriatric Depression Scale
short-form [39] (cut-off ≥7, to optimize specificity
[40]). Functional level was measured clinically with
the assistance of the Barthel Index [41]. Unless there
was co-existing physical disability, all patients diag-
nosed with SMC or MCI had a normal Barthel Index
score of 20/20.
Outcome measures
The Qmci has six subtests, covering five domains:
orientation, registration, clock drawing, delayed
recall, verbal fluency (VF) (a test of semantic verbal
fluency, e.g., naming of animals within one minute)
and logical memory (LM) (testing immediate verbal
recall of a short story) [27, 28]. Scored out of 100
points, it has a median administration time of 4.24
minutes [28]. The recommended cut-off score for CI
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(MCI or dementia) is <62 [42]. The MoCA is scored
out of 30 points and has seven subtests, covering five
cognitive domains: visuospatial/executive function,
naming, memory, attention, language, abstraction,
delayed recall and orientation [9, 25]. For screen-
ing in clinics, where high sensitivity is required, the
established MoCA threshold of <26 is suggested [9]
although a lower threshold (<24) may have better
predictive value [24].
Data collection
Consecutive referrals underwent a comprehensive
work-up including history, physical examination, lab-
oratory testing, neuropsychological assessment, and
neuroimaging, usually over two sessions, approxi-
mately six months apart, to maximize the accuracy
of the final diagnosis. Two informant-rated assess-
ments, the 8-item AD8 questionnaire [43, 44] and the
Informant Questionnaire on Cognitive Decline in the
Elderly-short form [45], were used to inform the diag-
nosis. Cognitive screening with the Qmci and MoCA
was performed in a random counterbalanced order,
alternating which of the two tests was scored first
to reduce learning or fatigue effects, approximately
one hour before consultant review, by two indepen-
dent trained raters, blind to each other and the final
diagnosis. Alternate validated versions of VF and LM
were used for the Qmci to reduce learning effects
[46]. Normal controls underwent a similar compre-
hensive review but did not undergo laboratory testing
or neuroimaging and few were available for a second
evaluation. The study adhered to the tenets of the Dec-
laration of Helsinki. Ethics approval was obtained
from the Clinical Research Ethics Committee of the
Cork Teaching Hospitals and where possible partici-
pants provided written consent; assent was obtained
from the relatives or caregivers of individuals who
were felt to lack capacity in accordance with current
Irish law.
Analysis
Data were analyzed using SPSS 20.0. The
Shapiro–Wilk test was used to test normality and
found that the majority of data were non-parametric.
These were compared using the Mann–Whitney U
test. Analysis of covariance (ANCOVA) was used to
control the results of analysis for age and education.
Accuracy was assessed with receiver operating char-
acteristics (ROC) curves, compared with the Hanley
method [47]. Binary logistic regression was used to
control ROC curves for the effects of age and educa-
tion. Sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) were cal-
culated for all tests at different cut-off points and
by age (≤75 and >75 to balance numbers between
groups) and education (<12 and ≥12, mean education
in the United Kingdom and Ireland [48]).
RESULTS
In total, 551 participants were included: 73 with
SMC, 103 with MCI, 274 with dementia, and 101
normal controls. Of those with MCI, 79% (n = 81)
were amnestic type MCI and 21% (n = 22) were
non-amnestic; 60% (n = 62) had deficits in a sin-
gle domain and 35% (n = 36) in multi-domains. Five
could not be clearly identified as single or multi-
domain. The median age of participants was 76
y (interquartile range, IQR ± 12) and the majority
were female (n = 363, 66%). Patients with demen-
tia (median age of 77 ± 10 years) were significantly
older than those with SMC (72 ± 11, p < 0.001), MCI
(76 ± 13, p = 0.03) and normal controls (74 ± 14,
p < 0.001). The median time in education was 12 ± 4
y. Those with dementia had spent less time in edu-
cation (11 ± 3 y) compared to those with SMC
(12 ± 4 y,p = 0.07), MCI (13 ± 5 y,p < 0.001), or con-
trols (13 ± 4 y, p < 0.001). There was no significant
difference in age (p = 0.82) or education (p = 0.16)
between those with SMC and controls. Patients with
MCI were of a similar age to those with dementia
(p = 0.06) but were significantly older than controls
(p = 0.01); they had also received more time in edu-
cation than patients with dementia (p < 0.001) and
normal controls (p < 0.001). To control for age and
education, ANCOVA was used to test differences
between participant groups. This confirmed a statis-
tically significant difference in Qmci scores between
all three groups (controls, MCI, and dementia),
irrespective of age or education, F(2,333) = 311.96,
p < 0.001, partialη2 = 0.65. A similar effect was found
for the MoCA: F(2,333) = 190.20, p < 0.001, partial
η2 = 0.53. The Qmci screen scores had a “stronger”
difference between the three groups compared to the
MoCA, based on a higher value of the partial eta-
squared (effect size).
The majority of patients with dementia were clas-
sified as early to mild stage dementia (n = 201,
73%). Participant characteristics, median test scores
according to diagnosis and the prevalence of MCI
and dementia subtypes are presented in Table 1.
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Table 1
Baseline characteristics of patients including the distribution of dementia and mild cognitive impairment (MCI) subtypes, median Quick
Mild Cognitive Impairment (Qmci) screen and Montreal Cognitive Assessment (MoCA) scores, with inter-quartile range (IQR) values, for
normal controls and patients with subjective memory complaints (SMC), MCI, and dementia
Group Total Normal SMC MCI Dementia Early-Mild Moderate Severe
Included Controls (Total)
Participants 551 101 73 103 274 201 61 12
Age
(Years) 76 ± 12 74 ± 14 72 ± 11 76 ± 13 77 ± 10 77 ± 9 79 ± 15 77 ± 11
(Median ± IQR)
(Q3-Q1) (81-69) (78-64) (78-67) (81-68) (82-72) (82-73) (84-69) (79-68)
Education
(Years) 12 ± 4 13 ± 4 12 ± 4 13 ± 5 11 ± 3 11 ± 3 10 ± 2 13 ± 3
(Median ± IQR)
(Q3-Q1) (14-10) (15-11) (14-10) (16-11) (13-10) (13-10) (11-9) (13-10)
Gender (% Female) 66% 69% 61% 66% 68% 68% 70% 58%
Qmci
(Median ± IQR) 51 ± 29 86 ± 13 68 ± 9 56 ± 12 37 ± 23 41 ± 14 18 ± 17 7 ± 6
(Q3-Q1)
(66-37) (81-68) (73-64) (64-52) (45-22) (46-32) (26-9) (9-3)
MoCA
(Median ± IQR) 20 ± 12 26 ± 4 25 ± 4 22 ± 5 13 ± 9 16 ± 7 6 ± 5 2 ± 3.5
(Q3-Q1)
(25-13) (28-24) (27-23) (25-20) (17-8) (19-12) (9-4) (3.5-0)
Subtype Alzheimer’s Vascular Mixed Frontotemporal Lewy Body Parkinson’s Other/
(possible/probable) disease unknown
Dementia (%) 176 (64%) 40 (15%) 24 (9%) 8 (3%) 12 (4%) 3 (1%) 11 (4%)
MCI (%) 72 (70%) 14 (13.5%) 8 (8%) 5 (5%) 3 (3%) 1 (0.5%) –
SMC – – – – – – –
Median administration time for the Qmci was
4.5 (±1.3) minutes, compared to 9.5 (±2.8) for
the MoCA.
Comparing the accuracy of the tests at differen-
tiating normal controls from MCI showed that the
Qmci had significantly greater accuracy, area under
the curve (AUC) of 0.90 (95% confidence interval:
0.86–0.94) than the MoCA, AUC of 0.80 (95% confi-
dence interval: 0.74–0.86), p = 0.009. The Qmci was
also significantly more accurate than the MoCA in
separating normal controls from patients with CI
(i.e., MCI and dementia), an AUC of 0.94 versus
0.90 respectively, p = 0.04. In their ability to discrim-
inate SMC from MCI, the Qmci had better (AUC
0.81) accuracy than the MoCA (AUC 0.73), p = 0.09,
albeit a non-significant difference. Both instruments
had similar, excellent accuracy at differentiating MCI
from dementia (AUC of 0.95 versus 0.91 respectively,
p = 0.2), and patients with SMC from CI (AUC of 0.97
versus 0.93 respectively, p = 0.23). Both were poor at
discriminating normal controls from SMC, (p = 0.28).
ROC curves are presented in Fig. 1. Correcting the
ROC curves for the effects of age and education
showed that the Qmci more accurately differentiated
MCI from normal controls (AUC of 0.94; 95% confi-
dence interval: 0.90–0.97) compared with the MoCA
(AUC of 0.84; 95% confidence interval: 0.77–0.90),
z = 2.76, p = 0.006, see Fig. 2a. The Qmci was also
significantly better at separating MCI from demen-
tia (AUC 1.00; 95% confidence interval: 0.998–1.00)
than the MoCA (AUC of 0.978; 95% confidence inter-
val: 0.96–0.99), a small but statistically significant
difference, z = 2.69, p = 0.007, see Fig. 2b.
The ability of both instruments to separate nor-
mal controls from CI was then assessed at different
cut-off scores. Patients with SMC were analyzed sep-
arately. At their established cut-offs, <62 for the Qmci
and <26 for the MoCA, the Qmci had a sensitivity of
90% and specificity of 87% (PPV of 0.96, NPV 0.70)
for CI, compared to 96% sensitivity and 58% speci-
ficity (PPV of 0.89, NPV 0.80) for the MoCA (<26).
At these cut-offs the MoCA had a false positive rate
of 11% compared to 4% for the Qmci; the MoCA
misclassified 42/101 (42%) of controls as having CI
compared to 13/101 (13%) with the Qmci. Increas-
ing the Qmci cut-off to <65 improved the sensitivity
(94%) but reduced the specificity (80%). Reducing
the MoCA cut-off for CI to <24 yielded an optimum
sensitivity and specificity for the test, 89% and 83%
respectively, and reduced the false positive rate to 5%.
Sensitivity, specificity, PPV, and NPVs are presented
in Table 2.
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Fig. 1. Receiver Operating Characteristic curves demonstrating the accuracy of the Quick Mild Cognitive Impairment (Qmci) screen and
Montreal Cognitive Assessment (MoCA) in differentiating (a) mild cognitive impairment (MCI) from normal controls, (b) MCI from
subjective memory complaints (SMC), (c) MCI and dementia, (d) normal controls from cognitive impairment (MCI and dementia), (e) SMC
from cognitive impairment, and (f) SMC from normal controls.
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Fig. 2. Comparison of the Receiver Operating Characteristic curves demonstrating the accuracy of the Quick Mild Cognitive Impairment
(Qmci) screen and Montreal Cognitive Assessment (MoCA) in differentiating (a) mild cognitive impairment (MCI) from normal controls
and (b) MCI from dementia. (note: data are adjusted for age and education)
Adjusting for age and education showed that the
Qmci was most sensitive and specific for CI in
patients with less education (<12 years), with a sen-
sitivity and specificity of 99% and 85% for those
aged ≤75; 97% and 74% respectively for those aged
>75 years. Sensitivity was lowest for younger patients
aged ≤75 with ≥12 years in formal education (74%).
The MoCA had similar excellent sensitivity (99%)
for older patients (>75) with less education (<12) but
very low specificity (37.5%). The MoCA had greater
sensitivity for those with more education. These val-
ues, adjusted for age and education, are presented in
Table 3. Reanalysis of the data comparing the ability
of the tests at their established cut-offs to differen-
tiate SMC from MCI and dementia showed similar
results, see Supplementary Material 2.
DISCUSSION
As populations age more patients are presenting to
increasingly busy outpatient clinics, many of which
are under-resourced [49], necessitating the use of
short instruments to identify MCI and monitor pro-
gression to dementia. Prompt diagnosis is particularly
important as new management strategies emerge [50,
51]. With multiple instruments available for MCI [52]
and dementia [53], choosing one instrument is chal-
lenging. This paper explores the accuracy, sensitivity,
and specificity of the Qmci and MoCA in their abil-
ity to detect CI (MCI and dementia) and differentiate
normal controls from SMC, MCI, and dementia.
The results suggest that the Qmci is briefer than
the MoCA and particularly accurate in distinguishing
MCI from controls. Both instruments had excellent
accuracy in separating MCI from dementia, and nor-
mal cognition and SMC from MCI and CI. The
results reaffirm the high sensitivity of the MoCA
but show that the Qmci has excellent sensitivity and
specificity. The established cut-off scores did not pro-
vide the highest sensitivity and specificity for either
instrument. At the widely used cut-off of <26 [9],
the MoCA had 96% sensitivity but only 58% speci-
ficity for detecting CI compared to 90% and 87%
respectively for the Qmci at a cut-off of <62 [42].
The poor specificity of the MoCA at this cut-off
is similar to results published elsewhere [12, 15,
17, 24, 26]. Specificity improved when the cut-off
was lowered and from this data, the optimal cut-
off appears to be that suggested by Damian et al.
at <24 [24]. The Qmci was associated with fewer
false positive results for CI, 4% at <62, compared
to 11% for the MoCA at <26. At this cut-off, a
large percentage of controls (42%) screened positive
using the MoCA. While high sensitivity is desir-
able for any screening test, false positive rates of
this magnitude may result in large numbers undergo-
ing unnecessary investigation, negating the purpose
of screening. Similar results were found for identi-
fying those with SMC. Indeed, neither instrument
was accurate in distinguishing SMC from normal
controls, which reflects the challenges in defining
this condition [54]. Although all patients received
interval assessment, this duration may not have been
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Table 2
Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV), with 95% confidence intervals (CI), for differ-
ent Quick Mild Cognitive Impairment (Qmci) screen and Montreal Cognitive Assessment (MoCA) cut-off scores for cognitive impairment
(mild cognitive impairment and dementia), without adjustment for age or education, compared with normal controls
Cognitive Sensitivity Specificity PPV NPV False False
Screen (95% CI) (95% CI) (95% CI) (95% CI) Positive Negative
Cut-off score (95% CI) (95% CI)
Prevalence of cognitive
impairment of 79%
Qmci
<65 94% 80% 94% 80% 6% 20%
(91–96) (71–87) (91–96) (71–87) (4–7) (13–29)
<64 93% 82% 95% 76% 5% 24%
(89–95) (73–89) (92–97) (69–84) (3–8) (16–33)
<63 91% 85% 96% 74% 4% 26%
(88–94) (76–91) (93–97) (64–81) (3–7) (19–36)
<62† 90% 87% 96% 70% 4% 30%
(86–93) (79–93) (93–98) (61–78) (2–7) (22–39)
<61 88% 92% 98% 69% 2% 31%
(84–91) (85–96) (95–99) (60–76) (1–5) (24–40)
<60 87% 93% 98% 67% 2% 33%
(83–90) (86–97) (95–99) (59–75) (1–5) (25–41)
<59 85% 96% 99% 65% 1% 35%
(81–89) (90–99) (96–100) (56–72) (0–4) (28–44)
<58 84% 98% 99% 64% 1% 36%
(80–88) (92–100) (97–100) (56–71) (0–3) (29–44)
<57 84% 100% 100% 64% 0% 36%
(79–87) (95–100) (98–100) (55–71) (0–2) (29–45)
<56 82% 100% 100% 61% 0% 39%
(78–86) (95–100) (98–100) (53–69) (0–2) (31–47)
<55 81% 100% 100% 59% 0% 41%
(76–85) (95–100) (98–100) (52–67) (0–2) (33–48)
MoCA
<26∗ 96% 58% 89% 80% 11% 20%
(93–98) (48–68) (85–92) (68–88) (8–15) (12–32)
<24∗∗ 89% 83% 95% 69% 5% 31%
(86–92) (74–90) (92–97) (60–77) (3–8) (23–40)
<23∗∗∗ 85% 86% 96% 62% 4% 38%
(81–88) (77–92) (93–97) (53–70) (3–7) (30–47)
<22∗∗∗∗ 78% 91% 97% 54% 3% 46%
(74–82) (83–96) (94–98) (46–62) (2–6) (38–54)
†Cut-off for cognitive impairment selected from O’Caoimh et al. [42]. ∗Cut-off for cognitive impairment selected from Nasreddine et al.
[9]. ∗∗Cut-off for cognitive impairment selected from Damian et al. [24]. ∗∗∗Cut-off for cognitive impairment selected from Luis et al. [12].
∗∗∗∗Cut-off for mild cognitive impairment selected from Freitas et al. [26].
sufficient to see progression in those diagnosed with
SMC.
This study also reaffirms that cognitive instruments
require adjustment for age and education. The Qmci
had low sensitivity in those with more time in formal
education (≥12 years) and the MoCA low speci-
ficity in those with less time in formal education (<12
years). This is similar to other studies demonstrating
that established MoCA cut-offs lack accuracy, partic-
ularly specificity, among older adults and those with
less time in formal education [22].
The study suggests several potential advantages
of the Qmci over the MoCA in this clinic sample.
The Qmci is more efficient because it takes half the
time to complete compared to the MoCA. The MoCA
had significant floor effects (median score of two
points in severe cases), making it particularly diffi-
cult for those with severe dementia to complete. As
the Qmci is scored from 100 points, each subtest pro-
vides more information. This is exemplified by the
scoring of the Clock. Although requiring more inter-
pretation, the scoring of the Qmci-Clock, provides
more detailed information and contributes more to
the final test score. The Qmci also incorporates fewer
subtests that require normal vision than the MoCA.
Visual impairment affects the performance of sub-
jects on cognitive testing, particularly in older adults
[55]. Visual tasks account for 27% of the MoCA’s
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Table 3
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and false positive and negative values for the Quick
Mild Cognitive Impairment (Qmci) screen and Montreal Cognitive Assessment (MoCA), based upon cut-off scores for cognitive impairment
(MCI and dementia), according to age and education (CI = 95% Confidence Interval)
Cognitive Age Edu Median N = X Cut-off Sensitivity Specificity PPV NPV False False
Screen Score score (95% CI) (95% CI) (95% CI) (95% CI) Positive Negative
(IQR) (95% CI) (95% CI)
Cognitive
Impairment
Controls
Qmci >75 <12 42 (50-26 = 24) 146/170 (86%) 97% 75% 96% 78% 4% 22%
70 (75-63 = 12) (92–99) (53–89) (91–98) (56–92) (2–7) (8–44)
>75 ≥12 47 (58-37 = 21) 59/76 (78%) <62 80% 94% 98% 55% 2% 49%
78 (81-71 = 10) (68–89) (69–100) (89–100) (36–73) (0–11) (27–64)
≤75 ≥12 47 (62-33 = 29) 73/110 (66%) 74% 95% 97% 64% 3% 36%
79 (84-75 = 9) (63–83) (80–99) (87–99) (50–76) (1–13) (24–50)
≤75 <12 41 (48-22 = 26) 77/97 (79%) 99% 85% 96% 94% 4% 6%
74.5 (82-65 = 17) (92–100) (61–96) (89–99) (71–100) (1–11) (0–29)
MoCA >75 <12 14.5 (19-10 = 9) 146/170 (86%) 99% 37.5% 91% 82% 9% 18%
25 (26-23 = 3) (95–100) (20–59) (85–94) (48–97) (6–15) (3–52)
>75 ≥12 19 (22-13 = 9) 59/76 (78%) <26 91.5% 71% 91.5% 71% 8% 29%
27 (29-25 = 4) (81–97) (44–89) (81–97) (44–89) (3–19) (11–56)
≤75 ≥12 18 (23-12 = 11) 73/110 (66%) 90% 73% 87% 79% 13% 21%
27 (30-25 = 6) (81–96) (56–86) (77–93) (62–91) (7–23) (9–38)
≤75 <12 16 (20-7 = 13) 77/97 (79%) 99% 50% 88% 91% 12% 9%
25.5 (27-24 = 3) (92–100) (28–72) (79–94) (57–100) (6–21) (1–43)
(Visuospatial/Executive and Naming) overall score
compared to 15% for the Qmci (clock drawing).
This said, both tests can be corrected to account for
incomplete data and recently a modified version of
the MoCA for the visually impaired has been vali-
dated [56]. However, the elimination of subtests that
require vision (naming, visuospatial and executive
function) reduces the discriminating function of the
‘MoCA-BLIND’, particularly its ability to differen-
tiate MCI from controls [56]. Given that this is the
principal advantage of the MoCA, suggests that it is
overly weighted towards visual tests, important when
assessing older adults [56]. The Qmci, on the other
hand, derives its accuracy for identifying MCI from
its delayed recall, VF, and LM subtests [28].
The main advantage of the MoCA is its sensi-
tivity, the most important psychometric property for
screening instruments [57], particularly in those with
higher levels of education. The Qmci however, pro-
vided an arguably better balance, particularly at a
higher cut-off (<65). The MoCA is less weighted
toward language, with 73% of the test requiring ver-
bal skills versus 85% for the Qmci. The MoCA is
validated widely, in different languages and clinical
settings. Validation of the Qmci in other countries,
languages, and cultures is now underway. The Qmci
is translated into several languages and is validated
in Dutch [58]. Future validation should also include
comparison with the MoCA and other screens for
MCI in different clinical populations such as the
Addenbrooke’s Cognitive Examination-III [59].
This study has a number of limitations. The sample
size was small, underpowering the study, potentially
causing bias, and limiting it to a non-inferiority
validation study. A power calculation, performed a
priori, suggested that approximately 300 participants
(normal controls and patients with MCI) would be
required to show superiority of one instrument over
the other in separating MCI from normal controls.
An attempt was made to classify patients with a
diagnosis and subtype where possible. However, as
this was a study in clinical practice, some demen-
tia subtypes may have been misclassified. Although
participants were screened in random order and alter-
native versions of tests were used, learning effects
may have occurred. Patients with SMC were diag-
nosed clinically and no specific screening test such
as the MAC-Q was used [60]. This said, a short Likert
scale in response to a single question could substitute
as a valid screen [38]. However, the type of instru-
ment selected may affect the diagnostic accuracy
and it is suggested that age-anchored reference ques-
tions provide the most utility [61]. As participants
were a homogenous sample (older Irish Caucasians),
attending a single center (a university hospital mem-
ory clinic), there is the potential that spectrum bias
may reduce the external validity. These effects have
been found for patients with MCI and are particularly
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affected by age and education [62]. As presented in
Table 3, participants’ age and education were seen
to affect the sensitivity and specificity of both the
MoCA and Qmci screen. Future validation studies,
using age and education specific cut-offs, could be
used to minimize this potential source of bias. Finally,
the high prevalence of cognitive impairment (68% of
the total sample) affects the ability to interpret the
accuracy of tests [57]. However, the high prevalence
seen and the characteristics of patients with demen-
tia (significantly older than normal controls) reflect
clinical practice.
In summary, this is the first study to compare a
short cognitive screen, designed specifically to dif-
ferentiate MCI from normal and dementia with the
MoCA in a “real-life” outpatient setting. While the
MoCA overcomes many of the difficulties associ-
ated with the MMSE, particularly in those with high
levels of education [63], the MoCA is long and has
suboptimal specificity among older adults attending
a memory clinic, particularly at its established cut-
off (<26). As older adults represent the majority of
patients who have cognitive screening performed for
symptoms of memory loss, the Qmci may be a shorter
and more accurate alternative, especially when used
with a higher cut-off score. The MoCA may be better
with a lower cut-off than the established score, par-
ticularly in older adults with high levels of education.
Further research is required to confirm these findings
and compare the Qmci and MoCA with other “MCI
specific” instruments and in different clinical settings,
particularly in primary care, where the brevity and
usability of the Qmci is likely to be of most benefit.
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